Peginterferon beta-1a (Plegridy) for multiple sclerosis

Med Lett Drugs Ther. 2015 May 11;57(1468):67-9.

Abstract

Pegylated interferon beta-1a (Plegridy) injected subcutaneously every 2 weeks appears to be similar in its efficacy and adverse effects to older interferon formulations that must be injected more frequently.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / methods
  • Humans
  • Injections, Subcutaneous
  • Interferon-beta / administration & dosage*
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Polyethylene Glycols / administration & dosage*

Substances

  • Polyethylene Glycols
  • Interferon-beta
  • peginterferon beta-1a